These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 7544833)

  • 41. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
    Weiss L; Nusair S; Reich S; Sidi H; Slavin S
    Cancer Immunol Immunother; 1996 Oct; 43(2):103-8. PubMed ID: 8954144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early induction of immune resistance against leukemia in lethally total body irradiated mice reconstituted with syngeneic bone marrow cells obtained from previously immunized donor mice.
    Skorski T; Kawalec M; Kawiak J
    Bone Marrow Transplant; 1990 Jan; 5(1):23-7. PubMed ID: 2297588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adoptive immunotherapy in canine chimeras.
    Kolb HJ; Günther W; Schumm M; Holler E; Wilmanns W; Thierfelder S
    Transplantation; 1997 Feb; 63(3):430-6. PubMed ID: 9039935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation.
    Xu H; Chilton PM; Huang Y; Schanie CL; Yan J; Ildstad ST
    Transplantation; 2007 Apr; 83(7):954-63. PubMed ID: 17460568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells.
    Shinagawa N; Yamazaki K; Tamura Y; Imai A; Kikuchi E; Yokouchi H; Hommura F; Oizumi S; Nishimura M
    Cancer Immunol Immunother; 2008 Feb; 57(2):165-74. PubMed ID: 17628800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunosuppressive effects of (131)I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models.
    Ruffner KL; Martin PJ; Hussell S; Nourigat C; Fisher DR; Bernstein ID; Matthews DC
    Cancer Res; 2001 Jul; 61(13):5126-31. PubMed ID: 11431350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of T lymphocyte depletion on susceptibility to influenza virus infection and development of anti-viral immunity in lethally irradiated mice reconstituted with syngeneic bone marrow grafts.
    Mumcuoglu M; Zakay-Rones Z; Parag G; Weiss L; Slavin S
    Bone Marrow Transplant; 1987 Dec; 2(4):403-12. PubMed ID: 3332187
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin.
    Kwak LW; Campbell MJ; Zelenetz AD; Levy R
    Blood; 1990 Dec; 76(11):2411-7. PubMed ID: 2257310
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors.
    Ilan Y; Nagler A; Shouval D; Ackerstein A; Or R; Kapelushnik J; Adler R; Slavin S
    Clin Exp Immunol; 1994 Aug; 97(2):299-302. PubMed ID: 8050180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation.
    Kohrt HE; Müller A; Baker J; Goldstein MJ; Newell E; Dutt S; Czerwinski D; Lowsky R; Strober S
    Blood; 2011 Nov; 118(19):5319-29. PubMed ID: 21868578
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery.
    Yamasaki Y; Ikenaga T; Otsuki T; Nishikawa M; Takakura Y
    Vaccine; 2007 Jan; 25(1):85-91. PubMed ID: 16956699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
    Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
    Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
    Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
    Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory.
    Dai J; Liu B; Caudill MM; Zheng H; Qiao Y; Podack ER; Li Z
    Cancer Immun; 2003 Jan; 3():1. PubMed ID: 12747743
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
    Azuma E; Yamamoto H; Kaplan J
    J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells.
    Ke Y; Kapp JA
    J Immunol; 1996 Feb; 156(3):916-21. PubMed ID: 8558017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
    Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
    Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.